BioPharmSignal logoBioPharmSignal

Biotech News

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus (ABUS)ArbutusCompany update

WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for

Related news

ABUSArbutus2026-10-01 11:30 EST

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

ABUSArbutus2026-08-24 11:30 EST

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

ASMBAssembly Biosciences2026-05-22 11:05 EST

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

MBRXMoleculin Biotech, Inc.2026-07-06 12:33 EST

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

View all latest news

Arbutus

Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...

Recent company news

ABUSArbutus2026-10-01 11:30 EST

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

ABUSArbutus2026-09-30 11:30 EST

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

ABUSArbutus2026-08-24 11:30 EST

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

ABUSArbutus2026-08-21 11:30 EST

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

ABUSArbutus2026-08-12 11:30 EST

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
4.56 USD
Market cap
841.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States